Checkpoint Therapeutics to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference

Rhea-AI Summary

Checkpoint Therapeutics (Nasdaq: CKPT) announced that CEO James Oliviero will participate in a fireside chat at B. Riley Securities’ 3rd Annual Oncology Conference on January 18, 2023, at 11:00 a.m. EST. This event will provide insights into Checkpoint's ongoing clinical developments, including its lead candidate, cosibelimab, an anti-PD-L1 antibody targeting solid tumors. Cosibelimab is currently in a Phase 1 trial for recurrent or metastatic cancers, particularly focusing on cutaneous squamous cell carcinoma. The company submitted a Biologics License Application in January 2023, following positive interim results.

WALTHAM, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities’ 3^rd Annual Oncology Conference, taking place on Wednesday, January 18, 2023, at 11:00 a.m. EST.

For more information and to register for the conference, please click here. A replay of the fireside chat will also be available on the registration link after the meeting.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc. (“Checkpoint”) is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in an ongoing open-label, multi-regional, multicohort Phase 1 clinical trial in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers, including cohorts in metastatic and locally advanced cutaneous squamous cell carcinoma (“cSCC”) intended to support one or more applications for marketing approval. Based on positive topline and interim results in metastatic and locally advanced cSCC, respectively, Checkpoint submitted a Biologics License Application for these indications in January 2023. Checkpoint is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib (formerly CK-101), a third-generation epidermal growth factor receptor (“EGFR”) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Checkpoint is headquartered in Waltham, MA and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.checkpointtx.com.

Company Contact:
Jaclyn Jaffe
Checkpoint Therapeutics, Inc.
(781) 652-4500
ir@checkpointtx.com

Investor Relations Contact:
Ashley R. Robinson
Managing Director, LifeSci Advisors, LLC
(617) 430-7577
arr@lifesciadvisors.com  

Media Relations Contact:
Katie Kennedy
Gregory FCA
610-731-1045
Checkpoint@gregoryfca.com 

FAQ

What is Checkpoint Therapeutics' participation in the B. Riley Securities Oncology Conference?

Checkpoint Therapeutics will have CEO James Oliviero participate in a fireside chat at the B. Riley Securities’ 3rd Annual Oncology Conference on January 18, 2023.

What time will the fireside chat by Checkpoint Therapeutics take place?

The fireside chat will occur at 11:00 a.m. EST on January 18, 2023.

What is the focus of Checkpoint Therapeutics at the conference?

Checkpoint Therapeutics will discuss its ongoing clinical developments, including the progress of its lead candidate, cosibelimab.

What are the key developments regarding cosibelimab for Checkpoint Therapeutics?

Cosibelimab is being evaluated in a Phase 1 trial for recurrent or metastatic cancers and has shown positive interim results, leading to a Biologics License Application submission in January 2023.

Where can I find more information about Checkpoint Therapeutics?

For more information, visit Checkpoint Therapeutics' website at www.checkpointtx.com.